← Eichor
Condition: Metabolic Dysfunction Associated Steatotic Liver Disease Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Metabolic Dysfunction Associated Steatotic Liver Disease

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Impact of Steatotic Liver Disease Associated With Metabolic Dysfunction (MASLD) on Frailty, Cognition, and Quality of Li
Phase N/A · 2 location(s) · Fundació Institut de Recerca de l'Hospital de la Santa Creu · NCT07652892
Management Concepts of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Among Chinese Physicians
Phase N/A · 1 location(s) · Novo Nordisk A/S · NCT07682363
Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population
Phase N/A · 1 location(s) · Ningbo No. 1 Hospital · NCT06984510
Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
NA · 1 location(s) · Phenomen Pharma · NCT07068191
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
Phase 2 · 5 location(s) · Regeneron Pharmaceuticals · NCT07527910
Implementing Food Referrals for Equity and Sustained Health
Phase 2 · 2 location(s) · University of California, San Diego · NCT06661538
Corazones Unidos Study
NA · 1 location(s) · University of Arizona · NCT07298213
Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH
Phase N/A · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06813508
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
Phase 1 · 3 location(s) · GlaxoSmithKline · NCT07358546
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
NA · 2 location(s) · Pichamol Jirapinyo, MD, MPH · NCT06138821
Fecal Microbiota Analysis of PNPLA3 Polymorphism in Hispanic Patients With MASLD
Phase N/A · 1 location(s) · Fundacion de Investigacion Science and Education · NCT06495333
Rehabilitation With Exercise-Based Intervention for Nonalcoholic Chronic Hepatic Esteatosis
NA · 1 location(s) · Universidad San Sebastián · NCT07552727
Effect of Insulin Lowering on Lipogenesis
Phase 1 · 1 location(s) · Columbia University · NCT07403604
A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV
Phase 2 · 10 location(s) · Naga P. Chalasani · NCT07143968
Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Non
NA · 3 location(s) · State Key Laboratory of Subhealth Intervention Technology · NCT07083336
Time-restricted Feeding in MASLD
NA · 1 location(s) · Universität des Saarlandes · NCT07530809
EVOO and Metabolic Liver Health in MASLD
NA · 1 location(s) · Azienda Ospedaliera Specializzata in Gastroenterologia Saver · NCT07412444
Spleen Stiffness Measurement for the Detection of Advanced Fibrosis
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT07440511
Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease
Phase N/A · 1 location(s) · Richmond Research Institute · NCT04873258
SMART Diets for MASLD
Phase 2 · 1 location(s) · Michigan State University · NCT07459504
Taiwan Green Propolis for Blood Lipids and Body Fat in Patients With MASLD
NA · 1 location(s) · Taipei Medical University · NCT07692438
A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
Phase N/A · 3 location(s) · Novartis Pharmaceuticals · NCT07683065
Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD
NA · 1 location(s) · Hospices Civils de Lyon · NCT07313007
The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patient
NA · 3 location(s) · University of Nottingham · NCT07093346
Targeting the Skeletal Muscle to Treat Metabolic Dysfunction-associated Steatotic Liver Disease
NA · 2 location(s) · Cliniques universitaires Saint-Luc- Université Catholique de · NCT06506513
Metabolic Features Effects on FAST Score in MASLD Patients
Phase N/A · 1 location(s) · Tanta University · NCT06867419
Efficacy of 12-week Daytime Restricted Eating on Hepatic Steatosis of Obesity
NA · 9 location(s) · Nantes University Hospital · NCT07378072
Developing Microbial Therapy for MASLD: From Mechanism to Clinical Validation
Phase 1 · 1 location(s) · Leeuwenhoek Laboratories Co. Ltd. · NCT07488975
Efficacy and Safety of Rifaximin-α in Treating MASLD
EARLY_Phase 1 · 1 location(s) · Shanghai Changzheng Hospital · NCT07381257
Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Diseas
Phase 2 · 1 location(s) · AB Biotics, SA · NCT07193927
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.